Cubist looks to dominate antibiotics game
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals could have multiple new drugs on the market within the next few years, making the hospital and acute care-focused company a dominant player in the antibiotics game based on its pipeline assets, acquisitions of Trius Therapeutics and Optimer Pharmaceuticals, and Cubist's advocacy for incentives to encourage antibiotic development.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports